Advertisement
Does Quick Heal Technologies' (NSE:QUICKHEAL) CEO Salary Compare Well With The Performance Of The Company?
The CEO of Quick Heal Technologies Limited (NSE:QUICKHEAL) is Kailash Katkar, and this article examines the executive's compensation against the backdrop of overall company performance. This analysis will also assess whether Quick Heal Technologies pays its CEO appropriately, considering recent earnings growth and total shareholder returns.
View our latest analysis for Quick Heal Technologies
Comparing Quick Heal Technologies Limited's CEO Compensation With the industry
Our data indicates that Quick Heal Technologies Limited has a market capitalization of ₹9.8b, and total annual CEO compensation was reported as ₹13m for the year to March 2020. We note that's a decrease of 9.2% compared to last year. We note that the salary portion, which stands at ₹11.9m constitutes the majority of total compensation received by the CEO.
On comparing similar-sized companies in the industry with market capitalizations below ₹15b, we found that the median total CEO compensation was ₹4.8m. Hence, we can conclude that Kailash Katkar is remunerated higher than the industry median. Furthermore, Kailash Katkar directly owns ₹2.9b worth of shares in the company, implying that they are deeply invested in the company's success.
| Component | 2020 | 2019 | Proportion (2020) |
| Salary | ₹12m | ₹12m | 90% |
| Other | ₹1.3m | ₹2.7m | 10% |
| Total Compensation | ₹13m | ₹15m | 100% |
Talking in terms of the industry, salary represents all of total compensation among the companies we analyzed, while other remuneration is, interestingly, completely ignored. Quick Heal Technologies sets aside a smaller share of compensation for salary, in comparison to the overall industry. If salary dominates total compensation, it suggests that CEO compensation is leaning less towards the variable component, which is usually linked with performance.
A Look at Quick Heal Technologies Limited's Growth Numbers
Over the last three years, Quick Heal Technologies Limited has shrunk its earnings per share by 2.8% per year. It saw its revenue drop 5.1% over the last year.
Its a bit disappointing to see that the company has failed to grow its EPS. This is compounded by the fact revenue is actually down on last year. It's hard to argue the company is firing on all cylinders, so shareholders might be averse to high CEO remuneration. We don't have analyst forecasts, but you could get a better understanding of its growth by checking out this more detailed historical graph of earnings, revenue and cash flow.
Has Quick Heal Technologies Limited Been A Good Investment?
With a three year total loss of 44% for the shareholders, Quick Heal Technologies Limited would certainly have some dissatisfied shareholders. Therefore, it might be upsetting for shareholders if the CEO were paid generously.
In Summary...
As previously discussed, Kailash is compensated more than what is normal for CEOs of companies of similar size, and which belong to the same industry. Disappointingly, share price gains over the last three years have failed to materialize. Arguably worse, we've been waiting for positive EPS growth for the last three years. Considering such poor performance, we think shareholders might be concerned if the CEO's compensation were to grow.
While it is important to pay attention to CEO remuneration, investors should also consider other elements of the business. We did our research and spotted 1 warning sign for Quick Heal Technologies that investors should look into moving forward.
Switching gears from Quick Heal Technologies, if you're hunting for a pristine balance sheet and premium returns, this free list of high return, low debt companies is a great place to look.
When trading Quick Heal Technologies or any other investment, use the platform considered by many to be the Professional's Gateway to the Worlds Market, Interactive Brokers. You get the lowest-cost* trading on stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted
Valuation is complex, but we're here to simplify it.
Discover if Quick Heal Technologies might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisThis article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
About NSEI:QUICKHEAL
Quick Heal Technologies
Engages in the provision of security software products and solutions to consumers, small businesses, government establishments, and corporate houses in India and internationally.
Flawless balance sheet with low risk.
Similar Companies
Market Insights
Advertisement
Weekly Picks
LO
Lou_Basenese on Optimi Health ·
The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist
Fair Value:US$1156.7% undervalued
52 followersusers have followed this narrative
2 commentsusers have commented on this narrative
9 likesusers have liked this narrative
BL
BlackGoat on IREN ·
IREN's Bold Moves in Sustainable Bitcoin Mining & AI Data Centers
Fair Value:US$71.4852.5% undervalued
205 followersusers have followed this narrative
6 commentsusers have commented on this narrative
32 likesusers have liked this narrative
HE
HedgeY on Arm Holdings ·
The Architecture Layer of AI Computing - But Priced Like the Future Already Arrived?
Fair Value:US$43043.1% undervalued
9 followersusers have followed this narrative
1 commentusers have commented on this narrative
3 likesusers have liked this narrative
HI
Hidden_Rock_Capital on Fiserv ·
Temporary "perfect storm" leads to opportunity to buy financial services leader for less than 5x long-term earnings
Fair Value:US$119.9954.8% undervalued
13 followersusers have followed this narrative
0 commentsusers have commented on this narrative
6 likesusers have liked this narrative
Recently Updated Narratives
ON
Ontological on Lotus Technology ·
Lotus Tech, Finloop and FOMO Pay Collaborate to Explore Vehicle Tokenization
Fair Value:US$2.463.7% undervalued
1 followerusers have followed this narrative
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
NE
newsfinder11221 on Robo.ai ·
Robo.ai (NASDAQ: AIIO): Building the Infrastructure Behind the AI Revolution
Fair Value:US$539.3% undervalued
1 followerusers have followed this narrative
3 commentsusers have commented on this narrative
0 likesusers have liked this narrative
EU
European_Hidden_Gem_Stocks on MINT Société anonyme ·
Mint SA: A French Micro-Cap Energy Retailer Worth Watching
Fair Value:€1153.1% undervalued
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Popular Narratives
CU
CubanEros on Microsoft ·
A wonderful business at reasonable price.
Fair Value:US$419.916.3% undervalued
89 followersusers have followed this narrative
0 commentsusers have commented on this narrative
6 likesusers have liked this narrative
OS
oscargarcia on NVIDIA ·
The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.
Fair Value:US$28029.6% undervalued
200 followersusers have followed this narrative
9 commentsusers have commented on this narrative
15 likesusers have liked this narrative
BE
benjamin_lvieq on PayPal Holdings ·
PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback
Fair Value:US$6510.3% undervalued
73 followersusers have followed this narrative
2 commentsusers have commented on this narrative
11 likesusers have liked this narrative
Trending Discussion
DE
derek_3wsdg on Teladoc Health ·
You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.
1
|0
